知镜 Cognispect · 医学文献与研究工作台

The Kv1.3 blocker PAP‑1 alleviates psoriasis‑like dermatitis in rats via suppressing inflammation and angiogenesis.

Yao F, Zhang Y, Zheng Y, Zhou R, Liu T, Wang L, Wang G, Yu Q, Sun D, Liu S, Tian C, Hu W.
Communications biology · 2026-07-20 · PMID 42477078

文献摘要

Psoriasis is a chronic inflammatory skin disorder driven by epidermal hyperplasia, immune infiltration, and pathological angiogenesis. PAP‑1, a selective Kv1.3 channel blocker, exhibits therapeutic potential, though its underlying mechanisms remain incompletely understood. Here, we show that both preventive and therapeutic administration of PAP‑1 markedly attenuates imiquimod (IMQ)-induced psoriasis‑like skin lesions and reduces splenomegaly in male rats. RNA sequencing revealed that PAP-1 downregulated genes associated with inflammation and angiogenesis, accompanied by decreased levels of pro-inflammatory cytokines and vascular markers. PAP-1 also inhibited VEGF-A-induced HUVEC proliferation, migration, invasion, and tube formation. Mechanistically, PAP-1 not only blocked Kv1.3 currents, but also suppressed Kv1.3 expression in the skin of IMQ-induced psoriasis-like male rats and VEGF-A-induced HUVECs. Cryo-EM structural analysis revealed that PAP-1 binds within the central cavity of Kv1.3, beneath the selectivity filter, in an inactivated state. These results establish that preventive and therapeutic PAP-1 alleviates psoriasis-like dermatitis via dual anti-inflammatory and anti-angiogenic mechanisms, supporting its further therapeutic development.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。